Tyra Biosciences to Present at Upcoming Investor Conferences

Rhea-AI Summary

Tyra Biosciences (Nasdaq: TYRA), a precision oncology company, announced its participation in two upcoming investor conferences. CEO Todd Harris will engage in a fireside chat at the Cowen 43rd Annual Healthcare Conference on March 7, 2023, at 10:30 am ET. Additionally, he will provide a company overview virtually at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 12:00 pm ET. Live and archived webcasts can be accessed through the Investor section of the TYRA website. Tyra focuses on developing therapies to combat tumor resistance, utilizing its proprietary SNÅP platform to design selective inhibitors targeting FGFR.

CARLSBAD, Calif., Feb. 22, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that management will present at the following investor conferences:

Cowen 43^rd Annual Healthcare Conference

• Todd Harris, CEO of TYRA, will participate in a fireside chat on Tuesday, March 7, 2023 at 10:30 am ET

Oppenheimer 33^rd Annual Healthcare Conference

• Mr. Harris will virtually present a company overview on Wednesday, March 15, at 12:00 pm ET

Live and archived webcasts of the events will be available via the For Investors page on the Investor section of the TYRA website.

About Tyra Biosciences

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. TYRA's proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Leveraging SNÅP, TYRA is developing a pipeline of selective inhibitors of Fibroblast Growth Factor Receptors (FGFR), which are altered in approximately 7% of all cancers. TYRA-300 is an FGFR3 selective inhibitor for oncology. TYRA-200 is an FGFR1/2/3 inhibitor with potency against FGFR2 fusions, molecular brake mutations and gatekeeper resistance that TYRA is developing initially in intrahepatic cholangiocarcinoma. TYRA is also targeting achondroplasia and other FGFR3-related skeletal dysplasias and FGFR4 and RET (REarranged during Transfection kinase) driven cancers. TYRA is based in Carlsbad, CA.  For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.

Contact:

Amy Conrad
aconrad@tyra.bio

View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-present-at-upcoming-investor-conferences-301753521.html

SOURCE Tyra Biosciences

FAQ

When is Tyra Biosciences presenting at the Cowen 43rd Annual Healthcare Conference?

Tyra Biosciences will present at the Cowen 43rd Annual Healthcare Conference on March 7, 2023, at 10:30 am ET.

What will Todd Harris present at the Oppenheimer 33rd Annual Healthcare Conference?

Todd Harris will present a company overview virtually at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 12:00 pm ET.

Where can I watch Tyra Biosciences' investor conference presentations?

Live and archived webcasts of Tyra Biosciences' presentations will be available on the Investor section of their website.

What is the focus of Tyra Biosciences?

Tyra Biosciences is focused on developing precision oncology therapies to overcome tumor resistance and improve cancer patient outcomes.

What is the purpose of Tyra's SNÅP platform?

The SNÅP platform is used to refine structural design and predict genetic alterations that cause acquired resistance to therapies.